The topic of this review is first to analyze in normal conditions the signal transduction pathways induced by members of the HER-ErbB receptor family and their ligands, and second, to decipher some deregulations occurring in various cancer types. As a result, new therapeutic opportunities will be mentioned.

ErbB Receptors↗

PubMed2002

[Update on . . . the proteasome inhibitor PS341].

The proteasome degradation system is one of the most efficient proteolytic process in living cells. We will focus here on a new compound, called PS341, which is the first proteasome inhibitor entering clinical phases. First results about its use in multiple myeloma or leukemic cells will be discussed.

Animals↗

PubMed2002

[The hypoxia-inducible factor HIF as a new target in cancer research].

The vascular endothelial growth factors (VEGF) plays major roles during tumor development. VEGF expression is regulated by the transcription factor HIF (hypoxia inducible factor) which is very sensitive to oxygene variations. We will show here that HIF1alpha is today a good prognostic and diagnostic marker for an increasing number of cancers from various origins. Furthermore, the reduction of the expression or the activity of HIF1alpha impairs tumour angiogenesis and subsequently growth. Altogether, these results suggest that HIF1alpha could be an interesting target in cancer therapy.

Animals↗

PubMed2002

[Beware of magic pills].

Explore the source record for details and available documents.

Anti-Inflammatory Agents, Non-Steroidal↗

PubMedDate not supplied

[Report on 93rd AACR].

Explore the source record for details and available documents.

Angiogenesis Inhibitors↗

PubMedDate not supplied

[Ras signals up there where no one expects it].

Explore the source record for details and available documents.

Cell Membrane↗